{"name":"Yun-Fan Liaw","slug":"yun-fan-liaw","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Placebo priming","genericName":"Placebo priming","slug":"placebo-priming","indication":"Chronic pain conditions","status":"marketed"}]}],"pipeline":[{"name":"Placebo priming","genericName":"Placebo priming","slug":"placebo-priming","phase":"marketed","mechanism":"Placebo priming leverages expectancy and conditioning effects to enhance the body's natural healing response through psychological and physiological mechanisms.","indications":["Chronic pain conditions","Depression and anxiety disorders","Irritable bowel syndrome","Parkinson's disease motor symptoms"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9Dc0hNb3VyTzhlVHpkRGlPZmNOYm9jMTByeVRZdmRoTzFnSDM0SVJzeTRRZUJPTDZxbDVEQWt4RlI1UVBwSFNrbHZhM01hWXFZX2V5SWpsdGloOEZRVjdj?oc=5","date":"2017-01-27","type":"pipeline","source":"NEJM","summary":"Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B - NEJM","headline":"Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBYZUtXRU1VdDBicUlhN3hlazZJZTFibG1wU2N3Qk1MdjJvY1lUQjN4RXdISFQxZ18xWVp6TndfT3pIajI4Rk1oUHkya25sb3RYUUNub2NZbDQ4cVhTdXRj?oc=5","date":"2004-10-07","type":"pipeline","source":"NEJM","summary":"Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease - NEJM","headline":"Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}